Cargando…
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori...
Autores principales: | Chauhan, Dharminder, Anderson, Kenneth C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203852/ https://www.ncbi.nlm.nih.gov/pubmed/22034840 http://dx.doi.org/10.1186/1741-7007-9-72 |
Ejemplares similares
-
The docking protein p130Cas regulates cell sensitivity to proteasome inhibition
por: Zhao, Ming, et al.
Publicado: (2011) -
p130Cas/BCAR1 and p140Cap/SRCIN1 Adaptors: The Yin Yang in Breast Cancer?
por: Centonze, Giorgia, et al.
Publicado: (2021) -
Extracurricular pursuits
por: Williams, Jonathan
Publicado: (2022) -
Conditional ablation of p130Cas/BCAR1 adaptor protein impairs epidermal homeostasis by altering cell adhesion and differentiation
por: Camacho Leal, Maria del Pilar, et al.
Publicado: (2018) -
Correction for The Integrin-coupled Signaling Adaptor p130Cas Suppresses Smad3 Function in Transforming Growth Factor-β Signaling
Publicado: (2011)